Literature DB >> 1527619

Aggravation of vasogenic cerebral edema by multiple-dose mannitol.

A M Kaufmann1, E R Cardoso.   

Abstract

The authors investigated the pharmacokinetics of mannitol administered for treatment of vasogenic cerebral edema. A cortical cold injury was produced in 23 cats maintained under general anesthesia for 5 or 21 hours. Control animals received no mannitol, while treatment groups received either a single dose or five doses administered at 4-hour intervals of 0.33 gm/kg radiolabeled mannitol. Liquid scintillation counting was carried out to determine the concentrations of mannitol in the cerebral tissue, cerebrospinal fluid, plasma, and urine. Cerebral water content and linear progression of edema were also measured. Rapid plasma clearance prevented accumulation of mannitol after multiple intravenous injections, as 84% +/- 2% (mean +/- standard error of the mean) of the infused mannitol was excreted through the urine. However, there was progressive accumulation of mannitol within the cerebral tissue, especially in the edematous white matter where it reached a level of 0.33 +/- 0.03 mg/gm after five doses, exceeding the trough plasma concentrations by a ratio of 2.69:1. Water content measurement showed that a single dose of mannitol failed to reduce cerebral water content or edema progression at 4 hours postinjection, while multiple doses produced a 3% increase in water content in edematous regions (p greater than 0.0003). The results of this study demonstrated a reversal of the osmotic concentration gradient between edematous brain and plasma following multiple mannitol injections, associated with exacerbation of vasogenic cerebral edema.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1527619     DOI: 10.3171/jns.1992.77.4.0584

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  54 in total

1.  Mass Effect with Cerebral Infarction.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-07       Impact factor: 3.598

Review 2.  Reprogramming the host response in bacterial meningitis: how best to improve outcome?

Authors:  M van der Flier; S P M Geelen; J L L Kimpen; I M Hoepelman; E I Tuomanen
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 3.  Osmotic therapy: fact and fiction.

Authors:  Michael N Diringer; Allyson R Zazulia
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 4.  Physiological and biochemical principles underlying volume-targeted therapy--the "Lund concept".

Authors:  Carl-Henrik Nordström
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 5.  Decompressive craniectomy as a therapeutic option in the treatment of hemispheric stroke.

Authors:  Justin F Fraser; Roger Hartl
Journal:  Curr Atheroscler Rep       Date:  2005-07       Impact factor: 5.113

6.  [Recommendations of the European Stroke Initiative for the diagnosis and treatment of spontaneous intracerebral haemorrhage].

Authors:  S Külkens; P Ringleb; J Diedler; W Hacke; T Steiner
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

Review 7.  The "Lund Concept" for the treatment of severe head trauma--physiological principles and clinical application.

Authors:  Per-Olof Grände
Journal:  Intensive Care Med       Date:  2006-08-02       Impact factor: 17.440

8.  Doubts over head injury studies.

Authors:  Ian Roberts; Richard Smith; Stephen Evans
Journal:  BMJ       Date:  2007-02-24

9.  Patterns of increased intracranial pressure after severe traumatic brain injury.

Authors:  Kristine H O'Phelan; Dalnam Park; Jimmy T Efird; Katherine Johnson; Melanie Albano; Juliet Beniga; Deborah M Green; Cherylee W J Chang
Journal:  Neurocrit Care       Date:  2009-01-23       Impact factor: 3.210

10.  Therapeutic targeting of astrocytes after traumatic brain injury.

Authors:  Jessica Shields; Donald E Kimbler; Walid Radwan; Nathan Yanasak; Sangeetha Sukumari-Ramesh; Krishnan M Dhandapani
Journal:  Transl Stroke Res       Date:  2011-11-09       Impact factor: 6.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.